A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Latest Information Update: 07 May 2024
At a glance
- Drugs Crizanlizumab (Primary)
- Indications Vaso-occlusive crisis
- Focus Adverse reactions; Pharmacokinetics
- Acronyms SOLACE-kids
- Sponsors Novartis; Novartis Healthcare; Novartis Pharmaceuticals
- 01 May 2024 Planned End Date changed from 12 Jun 2026 to 22 Jan 2025.
- 31 Jan 2024 Planned End Date changed from 11 Feb 2026 to 12 Jun 2026.
- 31 Jan 2024 Planned primary completion date changed from 31 May 2024 to 2 Jan 2025.